rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2015-446-451rsp-2117Research ArticleПЕДИАТРИЧЕСКАЯ РЕВМАТОЛОГИЯPEDIATRIC RHEUMATOLOGYКлиническое наблюдение применения тоцилизумаба при рефрактерном системном ювенильном артрите с поражением легких и синдромом активации макрофаговA CASE REPORT OF THE USE TOCILIZUMAB IN REFRACTORY SYSTEMIC JUVENILE ARTHRITIS WITH PULMONARY INVOLVEMENT AND MACROPHAGE ACTIVATION SYNDROMEКаледаМ. И.KaledaM. I.kaleda-mi@yandex.ruНикишинаИ. П.NikishinaI. P.РодионовскаяС. Р.RodionovskayaS. R.ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34АРоссияV.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522Russian Federation201510092015534446451Copyright © Каледа М.И., Никишина И.П., Родионовская С.Р., 20152015Каледа М.И., Никишина И.П., Родионовская С.Р.Kaleda M.I., Nikishina I.P., Rodionovskaya S.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2117

Представлено клиническое наблюдение применения тоцилизумаба (ТЦЗ) у пациента с рефрактерным системным ювенильным артритом, особенности терапевтического ответа в реальной клинической практике, рассмотрены аспекты индивидуальной безопасности ТЦЗ при развитии синдрома активации макрофагов и проведения сопутствующей терапии

The paper describes a patient with refractory systemic juvenile arthritis treated with tocilizumab (TCZ). Specific features of therapeutic response in real clinical practice, aspects of individual TCZ safety in the development of macrophage activation syndrome and concurrent therapy are discussed.

системный ювенильный артриттоцилизумабсиндром активации макрофаговбезопасностьsystemic juvenile arthritistocilizumabmacrophage activation syndromesafetyReferencesMellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7(7):416–26. doi: 10.1038/nrrheum.2011.68Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7(7):416–26. doi: 10.1038/nrrheum.2011.68Rabinovich CE. Juvenile Rheumatoid Arthritis. Medscapee Medicine Rheumatology. Available from: http://emedicine.medscape. com/article/1007276-overview. Updated June 1, 2010. Accessed March 1, 2010.Rabinovich CE. Juvenile Rheumatoid Arthritis. Medscapee Medicine Rheumatology. Available from: http://emedicine.medscape. com/article/1007276-overview. Updated June 1, 2010. Accessed March 1, 2010.Fujikawa S, Okuni M. Clinical analysis of 570 cases with juvenile rheumatoid arthritis: results of nationwide retrospective survey in Japan. Acta Paed Jpn. 1997;39(2):245–9. doi: 10.1111/j.1442- 200X.1997.tb03593.xFujikawa S, Okuni M. Clinical analysis of 570 cases with juvenile rheumatoid arthritis: results of nationwide retrospective survey in Japan. Acta Paed Jpn. 1997;39(2):245–9. doi: 10.1111/j.1442- 200X.1997.tb03593.xRavelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78. doi: 10.1016/S0140-6736(07)60363-8Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78. doi: 10.1016/S0140-6736(07)60363-8Алексеева ЕИ, Литвицкий ПФ. Ювенильный ревматоидный артрит. Руководство для врачей, преподавателей, научных сотрудников. Москва: ВЕДИ; 2007. 359 с. [Alekseeva EI, Litvitskii PF. Yuvenil'nyi revmatoidnyi artrit. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov [Juvenile rheumatoid arthritis. Guidelines for doctors, teachers, scientists]. Moscow: VEDI; 2007. 359 p.].Алексеева ЕИ, Литвицкий ПФ. Ювенильный ревматоидный артрит. Руководство для врачей, преподавателей, научных сотрудников. Москва: ВЕДИ; 2007. 359 с. [Alekseeva EI, Litvitskii PF. Yuvenil'nyi revmatoidnyi artrit. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov [Juvenile rheumatoid arthritis. Guidelines for doctors, teachers, scientists]. Moscow: VEDI; 2007. 359 p.].Behrens EM, Beukelman T, Gallo L, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol. 2008;35(2):343–8.Behrens EM, Beukelman T, Gallo L, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol. 2008;35(2):343–8.Cassidy JT. Juvenile rheumatoid arthritis. In: Cassidy JT, Petty RE, editors. Textbook of pediatric rheumatology. 4th ed. Philadelphia: W.B. Saunders Company; 2001:218–322.Cassidy JT. Juvenile rheumatoid arthritis. In: Cassidy JT, Petty RE, editors. Textbook of pediatric rheumatology. 4th ed. Philadelphia: W.B. Saunders Company; 2001:218–322.Baum J, Alekseev LS, Brewer EJ Jr. Juvenile rheumatoid arthritis. A comparison of patients from the USSR and USA. Arthritis Rheum. 1980;23(9):977–84. doi: 10.1002/art.1780230903Baum J, Alekseev LS, Brewer EJ Jr. Juvenile rheumatoid arthritis. A comparison of patients from the USSR and USA. Arthritis Rheum. 1980;23(9):977–84. doi: 10.1002/art.1780230903Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006;54(5):1595–601. doi: 10.1002/art.21774Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006;54(5):1595–601. doi: 10.1002/art.21774Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27(2):491–6.Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27(2):491–6.Grom AA, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996;129:630–2. doi: 10.1016/S0022-3476(96)70140-3Grom AA, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996;129:630–2. doi: 10.1016/S0022-3476(96)70140-3Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007 May; 34(5):1133–8. Epub 2007 Mar 1.Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007 May; 34(5):1133–8. Epub 2007 Mar 1.Davi S, Consolaro A, Guseinova D, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011;38:764–8. doi: http://dx.doi.org/10.3899/jrheum.100996Davi S, Consolaro A, Guseinova D, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011;38:764–8. doi: http://dx.doi.org/10.3899/jrheum.100996Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin N Am. 1991;17(4):891–905.Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin N Am. 1991;17(4):891–905.Still GF. On a form of chronic joint disease in children. 1896. Clin Orthop Relat Res. 1990 Oct;259:4–10.Still GF. On a form of chronic joint disease in children. 1896. Clin Orthop Relat Res. 1990 Oct;259:4–10.Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol. 2006;2(1):28–34. doi: 10.1038/ncprheum0084Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol. 2006;2(1):28–34. doi: 10.1038/ncprheum0084Yokota S, Miyamae T, Imagawa T, et al. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allerg Immunol. 2005;28:231–8. doi: 10.1385/CRIAI:28:3:231Yokota S, Miyamae T, Imagawa T, et al. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allerg Immunol. 2005;28:231–8. doi: 10.1385/CRIAI:28:3:231Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006. doi: 10.1016/S0140-6736(08)60454-7Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006. doi: 10.1016/S0140-6736(08)60454-7Yokota S, Imagawa T, Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic- onset juvenile idiopathic arthritis [SAT0536]. Ann Rheum Dis. 2009;68 Suppl 3:715.Yokota S, Imagawa T, Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic- onset juvenile idiopathic arthritis [SAT0536]. Ann Rheum Dis. 2009;68 Suppl 3:715.Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–8. doi: 10.1186/ar1826Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–8. doi: 10.1186/ar1826De Benedetti F, Brunner H, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95. doi: 10.1056/NEJMoa1112802De Benedetti F, Brunner H, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95. doi: 10.1056/NEJMoa1112802Kumar S, Kunhiraman DS, Rajam L. Application of the Yamaguchi criteria for classification of «suspected» systemic juvenile idiopathic arthritis (sJIA). Ped Rheumatol. 2012;10:40. doi: 10.1186/1546-0096-10-40Kumar S, Kunhiraman DS, Rajam L. Application of the Yamaguchi criteria for classification of «suspected» systemic juvenile idiopathic arthritis (sJIA). Ped Rheumatol. 2012;10:40. doi: 10.1186/1546-0096-10-40Reiff A. Treatment of systemic juvenile idiopathic arthritis with tocilizumab – the role of anti-interleukin-6 therapy after a decade of treatment. Biol Ther. 2012;2:1. doi: 10.1007/s13554-012-0001-6Reiff A. Treatment of systemic juvenile idiopathic arthritis with tocilizumab – the role of anti-interleukin-6 therapy after a decade of treatment. Biol Ther. 2012;2:1. doi: 10.1007/s13554-012-0001-6Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.doi: 10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R 25. Papadopoulou C, Kostik M, Gonzalez-Fernandez MI, et al. Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. Arthritis Care Res (Hoboken). 2013 Jul;65(7):1112–20. doi: 10.1002/acr.21947doi: 10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R 25. Papadopoulou C, Kostik M, Gonzalez-Fernandez MI, et al. Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. Arthritis Care Res (Hoboken). 2013 Jul;65(7):1112–20. doi: 10.1002/acr.21947Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598–604. doi: 10.1016/j.jpeds.2004.12.016Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598–604. doi: 10.1016/j.jpeds.2004.12.016Isaacs JD, Harari O, Kobold U, et al. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther. 2013;15(6):R204. doi: 10.1186/ar4397Isaacs JD, Harari O, Kobold U, et al. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther. 2013;15(6):R204. doi: 10.1186/ar4397Aoki C, Inaba Y, Choe H, et al. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. J Rheumatol. 2014;41:1171–7. doi: 10.3899/jrheum.130924Aoki C, Inaba Y, Choe H, et al. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. J Rheumatol. 2014;41:1171–7. doi: 10.3899/jrheum.130924

The authors declare that there are no conflicts of interest present.